Please assess the completion status of the following clinical trial:

Trial Title: Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Patients who had received a kidney, liver, lung or heart transplant more than 3 years prior to inclusion into the study~* Patients who had been treated at least 6 months prior to study entry with a stable twofold or threefold immunosuppressive treatment~* Patients who had clinically confirmed epithelial dysplasia (actinic keratoses) in at least two anatomically separated contralateral areas on the face and/or scalp with comparable size and extension and minimum distance of 5 cm~Exclusion Criteria:~* Invasive squamous cell carcinoma or basal cell carcinoma in the treatment area~* Known allergy to imiquimod and/or methyl-aminolaevulinate and/or one of the other components of the investigational products and/or peanut oil~* Patients who have received retinoids, interferons or investigational drugs within 4 weeks of study initiation~* Patients who are participating in othe dermatological study~* Persistent Hepatitis B or C infections~* Any evidence of systemic cancer~* Patients who have received any systemic cancer chemotherapy or radiation therapy~* Pregnant or lactating women~* Patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- photodynamic therapy (Type: EXPERIMENTAL): Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann \& Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
- imiquimod 5% cream (Type: ACTIVE_COMPARATOR): 250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).